Table 3. EGFR mutational analysis using Sanger and Next Generation sequencing.
| Biopsy Samples |
Number of mutated cases
|
Total Mutations observed
|
Mutations observed in samples with >40% of neoplastic cells
|
Mutations observed in samples with <40% of neoplastic cells
|
||||
|---|---|---|---|---|---|---|---|---|
| Sanger (%) | NGS (%) | Sanger | NGS | Sanger | NGS | Sanger | NGS | |
| N=14 | 3 (21.4)a | 6 (42.9)b | 4 | 9 | 4a | 8b | 0 | 1 |
| Del Ex19 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 |
| L858R | 1 | 2 | 1 | 2 | 1 | 1 | 0 | 1 |
| Other muts. | 1 | 5 | 1 | 5 | 1 | 5 | 0 | 0 |
| Cytology Samples | Number of mutated cases | Total Mutations observed | Mutations observed in samples with >40% of neoplastic cells | Mutations observed in samples with <40% of neoplastic cells | ||||
| Sanger (%) | NGS (%) | Sanger | NGS | Sanger | NGS | Sanger | NGS | |
| N=66 | 11 (16.7) | 18 (27.3)c | 11 | 22 | 11 | 14c | 0 | 8d |
| Del Ex19 | 8 | 12 | 8 | 12 | 8 | 9 | 0 | 3 |
| L858R | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 |
| Others muts. | 0 | 7 | 0 | 7 | 0 | 2 | 0 | 5 |
| All Samples | Number of mutated cases | Total Mutations observed | Mutations observed in samples with >40% of neoplastic cells | Mutations observed in samples with <40% of neoplastic cells | ||||
| Sanger (%) | NGS (%) | Sanger | NGS | Sanger | NGS | Sanger | NGS | |
| N=80 | 14 (17.5)a | 24 (30.0)d | 15 | 31 | 15a | 22c | 0 | 9b |
aIn one case double mutations were observed; bin two cases double/multiple mutations were observed; cin four cases double/multiple mutations were observed; din six cases double/multiple mutations were observed. NGS, Next Generation Sequencing; Del Ex19, deletion in exon 19; Other muts, mutations other than exon 19 deletion or L858R.